MétaCan
Menu
Back to cohort
Record W4254969812 · doi:10.1093/jcag/gwz006.218

A219 TRENDS IN TNF-ALPHA INHIBITOR UTILIZATION IN CHILDREN WITH IBD DURING THE LAST 10 YEARS: 2009–2018

2019· article· en· W4254969812 on OpenAlexaff
Ryma Iratni, Fatine Karkri, Colette Deslandres, Prévost Jantchou

Bibliographic record

VenueJournal of the Canadian Association of Gastroenterology · 2019
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsCentre Hospitalier Universitaire Sainte-JustineUniversité de Montréal
Fundersnot available
KeywordsMedicineAdalimumabInfliximabInflammatory bowel diseaseUlcerative colitisInternal medicineGastroenterologyCrohn's diseasePancolitisPopulationDiseaseColonoscopyColorectal cancer

Abstract

fetched live from OpenAlex

Since the last decade, anti-TNF have been increasingly used in the treatment of inflammatory bowel diseases (IBD), but the pattern of use is still not completely defined, especially in the pediatric population. We aimed to define the pattern of use of these monoclonal antibodies and the associated factors during the past ten years. We conducted a cross-sectional analysis of consecutive children with IBD (Crohn’s disease (CD), ulcerative colitis (UC) or unclassified colitis (IBDU)) at CHU Sainte-Justine who had received a treatment with an anti-TNF (Infliximab (IFX) or Adalimumab (ADA)) between January 2009 and October 2018. The primary outcome was the time between IBD diagnosis and the initiation of TNF-alpha inhibitor over the years. The secondary outcomes were the proportion of patients receiving that treatment within three months of diagnosis (early treatment), and the factors associated with early initiation (< 3 months after IBD diagnosis). Among the 925 patients diagnosed between January 2009 and October 2018, [(median (IQR) age at diagnosis 13.9 (4.5) years; 49% female; CD (n=622), UC (n=174), IBDU (n=129)], a total of 509 (55.0%) were exposed to anti-TNF. The median (IQR) PCDAI at diagnosis was 32.5 (20.0) for CD, and the median (IQR) PUCAI was 50.0 (35.0) in UC/IBDU. The median (IQR) age at start of anti-TNF was 14.1(4.5) years. The first exposition to anti-TNF was IFX (n=373), or ADA (n=46). Overall, the median (IQR) interval between IBD diagnosis and the initiation of TNF-alpha inhibitor was 117 (346) days. The median (IQR) interval was 354.0 (940.0) days for patients diagnosed in 2009–2010 and declined to reach 26.0 (101.0) days in 2017–2018. The rate of early treatment (<90 days) was 4.8% in 2009 and gradually increased to reach a maximum of 42.9% in 2018 (Table 1). In the cohort as a whole, the proportion of early treatment with anti-TNF was higher for CD (27.0%) and UC (31.0) than IBDU (6.9%), P<0.0001. A younger age at diagnosis was associated with an earlier start of anti-TNF (Hazard ratio = 1.40 (95% CI = 1.13–1.74); P= 0.0024). (Figure1) More than 50% of children are exposed to anti-TNF after a median follow-up of 4.1 years. Over the last few years, anti-TNF, are being used earlier in the course of IBD in children. A long-term follow-up of this cohort would be useful to assess whether the early anti-TNF approach impacts the long-term durability of remission and the long-term probability to remain under these drugs. Table 1: Change in Early Administration of Anti-TNF (Within 6 Months of IBD Diagnosis) During the Period 2009–2018 None

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.958
Threshold uncertainty score0.083

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0020.003
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.004
GPT teacher head0.197
Teacher spread0.193 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the Canadian Association of GastroenterologySame topicInflammatory Bowel DiseaseFrench-language works237,207